BR0006403A - Composição de dosagem oral de liberação prolongada estável - Google Patents

Composição de dosagem oral de liberação prolongada estável

Info

Publication number
BR0006403A
BR0006403A BR0006403-3A BR0006403A BR0006403A BR 0006403 A BR0006403 A BR 0006403A BR 0006403 A BR0006403 A BR 0006403A BR 0006403 A BR0006403 A BR 0006403A
Authority
BR
Brazil
Prior art keywords
hours
oral dosage
composition
release oral
dosage composition
Prior art date
Application number
BR0006403-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Jim H Kou
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22629437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0006403(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of BR0006403A publication Critical patent/BR0006403A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Toys (AREA)
  • Cosmetics (AREA)
BR0006403-3A 1999-12-20 2000-12-20 Composição de dosagem oral de liberação prolongada estável BR0006403A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17283699P 1999-12-20 1999-12-20

Publications (1)

Publication Number Publication Date
BR0006403A true BR0006403A (pt) 2001-07-17

Family

ID=22629437

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0006403-3A BR0006403A (pt) 1999-12-20 2000-12-20 Composição de dosagem oral de liberação prolongada estável

Country Status (37)

Country Link
US (2) US6979463B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP2196195A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (3) JP5042403B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (2) KR100936572B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (3) CN1679569A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR027033A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE463240T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (4) AU2277101A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR0006403A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2329217C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO5251435A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY1110693T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ302860B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE60044117D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK1112738T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EC (1) ECSP003836A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EG (1) EG23759A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2341751T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUP0004988A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ID (1) ID28675A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL140450A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA00013037A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY130773A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO331645B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ509028A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20010982A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL211573B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1112738E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (2) RU2303440C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SA (2) SA01210741B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG109438A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI1112738T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK287684B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (1) TR200003787A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI225414B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2001045668A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200007715B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045668A2 (en) 1999-12-20 2001-06-28 Schering Corporation Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
WO2001045676A2 (en) 1999-12-20 2001-06-28 Schering Corporation Extended release oral dosage composition
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
EP1401444A1 (en) * 2001-06-20 2004-03-31 Schering Corporation Antihistamines for the treatment of nasal congestion and nasal obstruction
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
EP1476138B8 (en) * 2002-02-21 2012-03-07 Valeant International (Barbados) SRL Modified release formulations of at least one form of tramadol
ATE352305T1 (de) * 2003-03-12 2007-02-15 Teva Pharma Stabile pharmazeutische zusammensetzungen mit desloratadine
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
EP1700591A4 (en) * 2003-12-01 2011-08-03 Takeda Pharmaceutical METHOD FOR THE TREATMENT OF A SOLID PHARMACEUTICAL PREPARATION BEFORE PRINTING AND PRESTIGIOUS SOLENOID PREPARATION TREATED BEFORE PRINTING
US20060110449A1 (en) * 2004-10-25 2006-05-25 Lorber Richard R Pharmaceutical composition
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
US20070014855A1 (en) * 2005-07-12 2007-01-18 Rahul Gawande S Stable desloratadine compositions
US20070036859A1 (en) * 2005-08-11 2007-02-15 Perry Ronald L Sustained release antihistamine and decongestant composition
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
US7827042B2 (en) 2005-11-30 2010-11-02 The Invention Science Fund I, Inc Methods and systems related to transmission of nutraceutical associated information
US20080103746A1 (en) 2005-11-30 2008-05-01 Searete Llc, A Limited Liability Corporation Systems and methods for pathogen detection and response
US8340944B2 (en) 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US7927787B2 (en) 2006-06-28 2011-04-19 The Invention Science Fund I, Llc Methods and systems for analysis of nutraceutical associated components
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
FR2894143B1 (fr) * 2005-12-01 2008-05-02 Pierre Fabre Medicament Sa Composition a liberation prolongee de l'actif, son procede de preparation et son utilisation.
RU2008151945A (ru) * 2006-06-01 2010-07-20 Шеринг Корпорейшн (US) Лекарственные формы с пульсирующим высвобождением и фармацевтические композиции фенилэфрина
NZ573174A (en) * 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
CL2007001584A1 (es) * 2006-06-01 2008-01-25 Msd Consumer Care Inc Composicion farmaceutica que comprende: un nucleo con fenilefrina en forma de liberacion inmediata y una capa erosionable que comprende fenilefrina y una matriz de liberacion sostenida; util para tratar los sintomas del resfriado, influenza, alergias o rinitis no alergicas.
SG172660A1 (en) * 2006-06-01 2011-07-28 Schering Corp Pharmaceutical compositions for sustained release of phenylephrine
MX2009000320A (es) * 2006-07-11 2009-06-05 Mutual Pharmaceutical Co Formulaciones de liberacion controlada.
RU2009148862A (ru) * 2007-06-01 2011-07-20 Шеринг-Плау Хельскер Продактс, Инк. (Us) Фармацевтическая композиция, включающая субстрат и покрытие, содержащее активный ингридиент и поливиниловый спирт
PE20091084A1 (es) * 2007-12-07 2009-07-23 Schering Plough Healthcare Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
DK3045043T3 (da) 2009-02-26 2020-08-03 Relmada Therapeutics Inc Orale farmaceutiske sammensætninger af 3-hydroxy-n-methylmorphinan med forlænget frigivelse og fremgangsmåde til anvendelse
WO2010143202A1 (en) * 2009-06-09 2010-12-16 Sun Pharmaceutical Industries Ltd. Pharmaceutical composition
TR201009396A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Desloratadin granüller
DE102016107760B4 (de) 2016-04-26 2018-09-20 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Essbare Funktionsschichten und Überzüge auf Hybridpolymerbasis für Pharmazie und Lebensmittel
US10463656B2 (en) 2017-01-05 2019-11-05 Iowa State University Research Foundation, Inc. Methods and compositions for prevention of feedlot bovine respiratory disease
EP4188339A1 (en) 2020-07-30 2023-06-07 Faes Farma, S.A. Decongestant drug delivery system

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US100000A (en) 1870-02-22 Improved sun-bonnet for horses
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3940485A (en) 1973-12-12 1976-02-24 Levinson Harold N Treatment and pre-treatment of dysmetric dyslexia by improving sequential scanning and ocular fixation abilities and therapeutic compounds
US4008796A (en) 1974-03-26 1977-02-22 General Concrete Of Canada Limited Control method for feeding items on a conveyor
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4282233B1 (en) 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
WO1985003707A1 (en) 1984-02-15 1985-08-29 Schering Corporation 8-CHLORO-6,11-DIHYDRO-11-(4-PIPERIDYLIDENE)-5H-BENZO AD5,6 BDCYCLOHEPTA AD1,2-b BDPYRIDINE AND ITS SALTS, PROCESSES FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS
US4783465A (en) 1984-04-09 1988-11-08 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4552899A (en) 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
SE8404467D0 (sv) 1984-09-06 1984-09-06 Ferrosan Ab Controlled-release medical preparations
US4731447A (en) 1985-05-13 1988-03-15 Schering Corporation Process for preparing piperidylidene dihydro-dibenzo(a,d)-cycloheptenes or aza-derivatives thereof
US4804666A (en) * 1985-08-14 1989-02-14 Schering Corporation Antiallergic 6,11-dihydro-11-(4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines
JPS6396126A (ja) 1986-10-13 1988-04-27 Taisho Pharmaceut Co Ltd 安定化組成物
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US4777170A (en) 1987-02-03 1988-10-11 Heinrich William A Method to prevent and treat the signs and symptoms of motion sickness
GB8707421D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
US4863931A (en) * 1988-09-15 1989-09-05 Schering Corporation Antihistaminic fluoro substituted benzocycloheptapyridines
US5019591A (en) * 1989-02-17 1991-05-28 Pennsylvania Research Corporation Method for treating retinopathy and other small vessel disorders associated with diabetes
US4990535A (en) 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
NZ238629A (en) 1990-06-22 1993-09-27 Schering Corp Bis-benzo- or benzopyrido-cyclohepta (where z is c, o, s or n) piperidine, piperidylidene or piperazine compounds, medicaments and methods of preparation
ATE139447T1 (de) 1990-12-18 1996-07-15 Wellcome Found Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
PT100502A (pt) 1991-05-20 1993-08-31 Alza Corp Composicoes farmaceuticas para aumentar a capacidade de permeacao na pele utilizando monolinoleato de glicerol
YU48263B (sh) 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
IL104192A (en) * 1992-02-17 1998-01-04 Siegfried Ag Pharma Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient
ES2042421B1 (es) 1992-05-22 1994-08-01 Uriach & Cia Sa J Procedimiento para la obtencion de la 8-cloro-11-*1-*(5-metil-3-piridil)metil*-4-piperidiliden*-6,11-dihidro-5h-benzo*5,6*ciclohepta*1,2-b*piridina.
US5314697A (en) * 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
IT1264517B1 (it) 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
JP2646972B2 (ja) 1993-11-01 1997-08-27 日本電気株式会社 多ビットメモリ
DE4442999A1 (de) 1994-12-02 1996-06-05 Hexal Pharma Gmbh Pharmazeutische Zusammensetzung mit einem aktiven Loratidin-Metaboliten
US5595997A (en) 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
US5807579A (en) * 1995-11-16 1998-09-15 F.H. Faulding & Co. Limited Pseudoephedrine combination pharmaceutical compositions
JP3220373B2 (ja) * 1995-11-28 2001-10-22 バイエル薬品株式会社 持続性ニフエジピン製剤
JP2000505104A (ja) * 1996-10-31 2000-04-25 シェーリング コーポレイション 喘息の治療のためのロラタジンおよび充血除去剤を含む組成物
PE71699A1 (es) * 1997-02-07 1999-08-03 Sepracor Inc Composicion farmaceutica de descarboetoxiloratadina sin lactosa, no higroscopica y anhidra
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
US5939426A (en) * 1997-02-28 1999-08-17 Sepracor Inc. Methods for treating urinary incontinence using descarboethoxyloratadine
US6506767B1 (en) * 1997-07-02 2003-01-14 Schering Corporation 8-chloro-6,11-dihydro-11-(4-piperidylidine)-5H-benzo[5,6]cyclohepta[1-2-b] pyridine
CA2307790A1 (en) * 1997-10-29 1999-05-06 J-Med Pharmaceuticals, Inc. Antihistamine/decongestant regimens for treating rhinitis
US6132758A (en) * 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
SK288240B6 (sk) 1998-07-10 2015-02-03 Merck Sharp & Dohme Corp. Farmaceutický prostriedok na orálne podávanie
US6423721B1 (en) 1998-09-10 2002-07-23 Schering Corporation Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
US6521254B2 (en) * 1998-12-07 2003-02-18 J-Med Pharmaceuticals, Inc. Single-dose antihistamine/decongestant formulations for treating rhinitis
US6051585A (en) * 1998-12-07 2000-04-18 Weinstein; Robert E. Single-dose antihistamine/decongestant formulations for treating rhinitis
US6100274A (en) 1999-07-07 2000-08-08 Schering Corporation 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
US6114346A (en) * 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine
WO2001045668A2 (en) 1999-12-20 2001-06-28 Schering Corporation Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
WO2001045676A2 (en) 1999-12-20 2001-06-28 Schering Corporation Extended release oral dosage composition
MXPA02007558A (es) 2000-02-03 2002-12-13 Schering Corp Tratamiento de condiciones inflamatorias alergicas.
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
CA2408145A1 (en) 2000-05-19 2001-11-29 Mark R. Hellberg Aniline disulfide derivatives for treating allergic diseases
US6599913B1 (en) 2001-06-29 2003-07-29 Schering Corporation Treating allergic and inflammatory conditions

Also Published As

Publication number Publication date
JP2008081510A (ja) 2008-04-10
JP2012224642A (ja) 2012-11-15
EP1112738A3 (en) 2001-07-18
CA2329217C (en) 2006-10-31
NO20006504L (no) 2001-06-21
HUP0004988A2 (hu) 2002-11-28
PL211573B1 (pl) 2012-05-31
CN1301534A (zh) 2001-07-04
ECSP003836A (es) 2002-02-25
KR100936572B1 (ko) 2010-01-13
EG23759A (en) 2007-08-08
IL140450A (en) 2011-11-30
CN1211079C (zh) 2005-07-20
ZA200007715B (en) 2001-06-20
IL140450A0 (en) 2002-02-10
ES2341751T3 (es) 2010-06-28
WO2001045668A2 (en) 2001-06-28
HK1034453A1 (en) 2001-10-26
CN101081224A (zh) 2007-12-05
DE60044117D1 (de) 2010-05-20
HUP0004988A3 (en) 2008-04-28
US20060159761A1 (en) 2006-07-20
AU781924B2 (en) 2005-06-23
MXPA00013037A (es) 2003-06-19
SI1112738T1 (sl) 2010-07-30
ATE463240T1 (de) 2010-04-15
TR200003787A2 (tr) 2001-07-23
CN101081224B (zh) 2012-05-30
AU2277101A (en) 2001-07-03
KR101234940B1 (ko) 2013-02-19
AU7244300A (en) 2001-06-21
PE20010982A1 (es) 2001-09-28
SG109438A1 (en) 2005-03-30
AR027033A1 (es) 2003-03-12
DK1112738T3 (da) 2010-06-28
AU2009200460A1 (en) 2009-02-26
NO20006504D0 (no) 2000-12-20
ID28675A (id) 2001-06-21
JP2001172174A (ja) 2001-06-26
SA01210741A (ar) 2005-12-03
US20030086971A1 (en) 2003-05-08
US6979463B2 (en) 2005-12-27
TR200003787A3 (tr) 2001-07-23
SK287684B6 (sk) 2011-06-06
CN1679569A (zh) 2005-10-12
AU2005203771A1 (en) 2005-09-15
SA06270069B1 (ar) 2009-06-07
PL344715A1 (en) 2001-07-02
SA01210741B1 (ar) 2006-10-31
MY130773A (en) 2007-07-31
RU2423106C9 (ru) 2012-06-27
EP1112738A2 (en) 2001-07-04
CA2329217A1 (en) 2001-06-20
PT1112738E (pt) 2010-06-04
US7820199B2 (en) 2010-10-26
RU2007104095A (ru) 2008-08-10
HU0004988D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2001-02-28
JP5042403B2 (ja) 2012-10-03
AU2009200460B2 (en) 2012-01-19
CY1110693T1 (el) 2015-06-10
NZ509028A (en) 2002-12-20
EP2196195A3 (en) 2012-02-29
RU2303440C2 (ru) 2007-07-27
KR20010062542A (ko) 2001-07-07
EP1112738B1 (en) 2010-04-07
KR20110028326A (ko) 2011-03-17
NO331645B1 (no) 2012-02-13
CZ302860B6 (cs) 2011-12-21
CO5251435A1 (es) 2003-02-28
RU2423106C2 (ru) 2011-07-10
SK19672000A3 (sk) 2001-09-11
EP2196195A2 (en) 2010-06-16
TWI225414B (en) 2004-12-21
CZ20004812A3 (cs) 2001-08-15
WO2001045668A3 (en) 2001-12-13

Similar Documents

Publication Publication Date Title
BR0006403A (pt) Composição de dosagem oral de liberação prolongada estável
NO951527L (no) Stabilt, oralt doseringspreparat med forlenget frigivelse
PT1446119E (pt) Substancias que contem ipratropio e xilometazolina na sua composicao para o tratamento da constipacao comum
BRPI0414435A (pt) métodos e reagentes para o tratamento de distúrbios imunoinflamatórios
BR0317134A (pt) Composições e métodos de liberação de agentes farmacológicos
CY1106430T1 (el) Φαρμακα για εισπνοη που πepιλαμβανουν βηταμιμητικα και αντιχολινepγικο
WO2003039436A3 (es) Composiciones farmaceuticas que contienen oxibutinina
BR9813827A (pt) Analgésico opióide aplicável em mamìferos e método para impedir o uso oral abusivo de uma formulação opióide oral
BR0000003A (pt) Azalidas e métodos de preparação das mesmas
BR0012082A (pt) Formulação farmacêutica para administração compreendendo morfina e seu uso
Kölker et al. Potentiation of 3‐hydroxyglutarate neurotoxicity following induction of astrocytic iNOS in neonatal rat hippocampal cultures
BR9909138A (pt) Combinação para o tratamento de dependência de álcool e drogas contendo um antagonista de opióide e um modulador de complexo receptor de nmda
BR0014946A (pt) Uso de dipiridamol ou mopidamol na fabricação de um medicamento para o tratamento e prevenção de distúrbios da microcirculação dependentes da fibrina
Förstermann Regulation of nitric oxide synthase expression and activity
BR0107721A (pt) Combinação, uso de mirtapazina e gepirona, método para o tratamento de depressão ou de um distúrbio relacionado em um indivìduo de uma espécie vertebrada, e, kit de paciente que contém meios para a administração de doses unitárias dosadas
BRPI0416882A (pt) composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BR0207866A (pt) Uso de flumazenil na preparação de um medicamento para o tratamento da dependência de cocaìna
BR0108261A (pt) Uso de mirtazapina, método de tratamento de um distúrbio do sono em um indivìduo, e, kit para paciente para o tratamento de distúrbios do sono
BRPI0410374A (pt) composição farmacêutica que compreende valsartano
Guglielmo et al. Topiramate, naltrexone, and acamprosate in the treatment of alcohol use disorders
BR0009704A (pt) Utilização do osanetant para a preparação de medicamentos úteis no tratamento das perturbações do humor
Forte Paracetamol: safety versus toxicity
Glazier Potentiation of pain relief with hydroxyzine: a therapeutic myth?
BR0016469A (pt) Composição para melhorar a resposta proliferativa durante a adaptação do trato gastrointestinal e uso na sìndrome do intestino delgado
BR9812466A (pt) Uso de ifn-alfa e amantadina para o tratamento da hepatite c crÈnica

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B25G Requested change of headquarter approved

Owner name: MERCK SHARP AND DOHME CORP. (US)